ADMP Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update. The company’s press release concerning its second quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on August 10, 2022, and on its . 

Event: Adamis Pharmaceuticals Second Quarter 2022 Financial Results Conference Call 

Date: Wednesday, August 10, 2022 

Time: 1:30 p.m. PT (4:30 p.m. ET) 

U.S. Dial-in (Toll Free): 1-877-423-9813 

Toll/International Dial-in: 1-201-689-8573 

Conference ID: 13731678 

David J. Marguglio, President and CEO of Adamis, will host the call along with other members of the management team. The call is open to the public and will provide an update on recent developments, events that have taken place during the year, and certain goals for future periods. Forward-looking statements concerning expectations regarding future company performance may be made during the conference call. 

A live audio webcast of the conference call will also be available via this , with a replay available shortly after the live event. 

About Adamis Pharmaceuticals 

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s ® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ™ (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For additional information about Adamis Pharmaceuticals, please visit our and follow us on and .

Contact: 

Adamis Investor Relations

Robert Uhl 

Managing Director 

ICR Westwicke

619.228.5886 



EN
08/08/2022

Underlying

ADMPAdamis Pharmaceuticals Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adamis Pharmaceuticals Corp

 PRESS RELEASE
Free
ADMP Adamis Pharmace...

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, announces that it has regained the full rights to commercialize ZIMHI® (naloxone) after the termination of an exclusive commercialization and distribution with US WorldMeds, LL...

December 21, 2023 1 EN
 PRESS RELEASE
Free
ADMP Adamis Pharmace...

DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI®...

DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update Now seeking out license opportunities for SYMJEPI® SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and SYMJEPI® (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previou...

November 28, 2023 1 EN
 PRESS RELEASE
Free
ADMP Adamis Pharmace...

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and P...

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value Developed holistic company growth strategy to create a cost effective, coordinated, streamlined approach to operations to increase value for patients and shareholders Presented preclinical data for DPI-125 at the Society of Neuroscience Annual Meeting 2023 on Nove...

November 14, 2023 1 EN
 PRESS RELEASE
Free
ADMP Adamis Pharmace...

DMK Pharmaceuticals Announces Presentation of Preclinical Results Comp...

DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023 SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of...

November 13, 2023 1 EN
 PRESS RELEASE
Free
ADMP Adamis Pharmace...

DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Lis...

DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board of directors approved the grant of a stock option on October 23, 2023, to purchase an aggregate of 70,000 shares of common stock to John W. Dorbin, Jr., a newly hired employee who was appointed as General Counsel and Corporate Secretary of the company. The stock option was granted as a material inducement to his acceptance of employme...

October 30, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch